Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

NSCLC: KOL Insight: Update Bulletin [May 2017]

Product Code:
596200620
April Date:
May 2017
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in non-small cell lung cancer (NSCLC), including: the EU approval of Novartis’s Mekinist (trametinib) in combination with Tafinlar (dabrafenib) for the treatment of BRAF V600-positive advanced NSCLC; Takeda's Alunbrig (brigatinib) being granted accelerated approval in the US for the treatment of patients with metastatic ALK-positive NSCLC who have progressed on or are intolerant to Xalkori (crizotinib; Pfizer); the Phase III ALEX study demonstrating Roche’s Alecensa (alectinib) to be superior to Xalkori in terms of progression-free survival (PFS) in the first-line treatment of ALK-positive NSCLC; and AbbVie’s PARP inhibitor, veliparib, failing to meet its primary endpoint of overall survival (OS) in a Phase III trial in NSCLC.

Business Questions:

  • How do KOLs view the EU approval of Novartis’s Mekinist in combination with Tafinlar for the treatment of BRAF V600-positive advanced NSCLC?
  • Where do KOLs see Mekinist plus Tafinlar fitting into the NSCLC treatment algorithm?
  • What factors could curtail the use of Mekinist in combination with Tafinlar?
  • How do KOLs view the US approval of Takeda's Alunbrig and data from the ALTA trial?
  • Where will Alunbrig be best positioned in the NSCLC treatment algorithm?
  • How do KOLs view the positive outcome from the ALEX trial of Roche’s Alecensa and what will determine its success in first-line therapy?
  • To what extent will Alecensa be used in the first-line treatment of ALK-positive NSCLC?
  • How is the second-line treatment of ALK-positive NSCLC likely to evolve in light of recent events?
  • How do KOLs view the Phase III failure of AbbVie’s veliparib and the future of PARP inhibitors in NSCLC?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved